Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 201–300 of 1,006
(2001) · PubMed · Cited by 292
Harris, C. C. (1996) · Carcinogenesis · doi:10.1093/carcin/17.6.1187 · Cited by 285
104 candidate genes for the hypoxic tumor phenotype
Koong, A. C., Denko, N. O., Schindler, C., Le, Q. T., Terris, D. T., Ibrahim, H. Z., Goffinet, D. R., & Giaccia, A. J. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)90122-0 · Cited by 285
Self-citationLiao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 261
Oncogenic ras and p53 Cooperate To Induce Cellular Senescence
Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., & Lowe, S. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3497-3508.2002 · Cited by 290
“The stimuli that regulate p53 activity include DNA damage (34, 39), altered ribonucleotide pools (30), hypoxia (14, 15), oncogenes (4, 19, 31, 49, 56, 61), cell adhesion (40), mitotic spindle defects (3), and redox stress (17, 45).”
BackgroundSelf-citationp53 Inhibits Hypoxia-inducible Factor-stimulated Transcription
Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., & Neckers, L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.11995 · Cited by 283
Progress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
Hammond, E. M., Dorie, M. J., & Giaccia, A. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212360200 · Cited by 284
Self-citationControl of the cell cycle and apoptosis
Weinberg, R. A., & Lundberg, A. S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00046-5 · Cited by 285
Wartenberg, M., Ling, F. C., Müschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Pütz, V., Hescheler, J., & Sauer, H. (2003) · The FASEB Journal · doi:10.1096/fj.02-0358fje · Cited by 287
“In a solid tumor in vivo, a number of factors associated either directly or indirectly with tumor hypoxia contribute to resistance to anticancer drugs (10).”
BackgroundBraun, R. D., Lanzen, J. L., Snyder, S. A., & Dewhirst, M. W. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.280.6.h2533 · Cited by 285
“Hypoxia has recently been shown to increase mutation frequency (29), to exert a selective pressure for survival of those cells with lower apoptotic potential (12), to alter gene expression of genes involved in cell cycle regulation and cytokine production (6), and to impact treatment outcome and patient survival (3, 1…”
BackgroundHypoxia and defective apoptosis drive genomic instability and tumorigenesis
Nelson, D. A., Tan, T.-T., Rabson, A. B., Anderson, D., Degenhardt, K., & White, E. (2004) · Genes & Development · doi:10.1101/gad.1204904 · Cited by 281
“Indeed, hypoxia in tumors is associated with poor prognosis and may promote tumor progression (Graeber et al. 1996; Harris 2002), although the basis for this is not entirely clear.”
BackgroundStructure-Function Comparisons of the Proapoptotic Protein Bax in Yeast and Mammalian Cells
Zha, H., Fisk, H. A., Yaffe, M. P., Mahajan, N., Herman, B., & Reed, J. C. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6494 · Cited by 282
“Similarly, Bcl-2 and Bcl-XL can prevent cell death induced in vitro by hypoxia, an insult typically considered to be a classical inducer of necrotic cell death (15, 27, 67).”
Hypoxia-Inducible Factor 1: Control of Oxygen Homeostasis in Health and Disease
Semenza, G. L. (2001) · Pediatric Research · doi:10.1203/00006450-200105000-00002 · Cited by 279
Bussink, J., Kaanders, J. H. A. M., & van der Kogel, A. J. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(03)00011-2 · Cited by 276
“Hypoxia stimulates the growth of p53-mutated sublines in tumors by reducing apoptosis in cells with a loss of the p53 tumor suppressor gene or by over-expression of the apoptosis-inhibitor protein bcl-2 [50].”
BackgroundKorbecki, J., Kojder, K., Kapczuk, P., Kupnicka, P., Gawrońska-Szklarz, B., Gutowska, I., Chlubek, D., & Baranowska-Bosiacka, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020843 · Cited by 273
“Its proapoptotic effect on cells results in a selection of cells in terms of apoptosis resistance, a process which is important at the beginning of tumor development and results in the presence of cancer cells with a p53 dysfunction in the tumor [49].”
BackgroundHypoxia, gene expression, and metastasis
Chan, D. A., & Giaccia, A. J. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9063-1 · Cited by 276
Self-citationKawamura, T., Kusakabe, T., Sugino, T., Watanabe, K., Fukuda, T., Nashimoto, A., Honma, K., & Suzuki, T. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<634::aid-cncr1364>3.0.co;2-x · Cited by 276
Reciprocal influence of the p53 and the hypoxic pathways
Sermeus, A., & Michiels, C. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.48 · Cited by 265
A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis
Friedlander, P., Haupt, Y., Prives, C., & Oren, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4961 · Cited by 278
Tea and Cancer Prevention: Studies in Animals and Humans
Chung, F.-L., Schwartz, J., Herzog, C. R., & Yang, Y.-M. (2003) · The Journal of Nutrition · doi:10.1093/jn/133.10.3268s · Cited by 275
Komarova, E. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1391 · Cited by 273
Cell-cycle control and its watchman
Jacks, T., & Weinberg, R. A. (1996) · Nature · doi:10.1038/381643a0 · Cited by 274
Self-citationChang, Q., Jurisica, I., Do, T., & Hedley, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4049 · Cited by 272
“Hypoxia tolerance can occur due to genetic changes such as p53 loss that enhance cell survival (7), or to cellular responses to hypoxia, driven for example by hypoxia-inducible factors (HIFs) or the unfolded protein response, that modify gene expression, cell phenotype, and metabolism (8, 9).”
BackgroundResultHypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation
Dachs, G. U., & Tozer, G. M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00159-3 · Cited by 272
“Hypoxia-induced apoptosis was found to be reduced in cells lacking p53, and small numbers of cells lacking p53 could outgrow similar p53 wild-type cells under hypoxia in vitro [72].”
BackgroundInhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260
“Hypoxia-induced apoptosis, for example, seems to be at least partially dependent on p53 [89], and when grown under hypoxic conditions, cells harboring p53 mutations rapidly overtake wild-type p53 counterparts, which clearly shows the selective advantage that p53 null cells have under hypoxic conditions [90].”
BackgroundRheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases
Tak, P. P., Zvaifler, N. J., Green, D. R., & Firestein, G. S. (2000) · Immunology Today · doi:10.1016/s0167-5699(99)01552-2 · Cited by 268
Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
Stadler, P., Becker, A., Jürgen Feldmann, H., Hänsgen, G., Dunst, J., Würschmidt, F., & Molls, M. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00115-7 · Cited by 266
Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α
Chan, D. A., Sutphin, P. D., Denko, N. C., & Giaccia, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206922200 · Cited by 264
Self-citationPrognostic significance of tumor oxygenation in humans
Evans, S. M., & Koch, C. J. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00012-0 · Cited by 259
Self-citationGenomic amplification and oncogenic properties of the KCNK9 potassium channel gene
Mu, D., Chen, L., Zhang, X., See, L.-H., Koch, C. M., Yen, C., Tong, J. J., Spiegel, L., Nguyen, K. C. Q., Servoss, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00054-0 · Cited by 263
Self-citationThe role of oxygen in regulating neural stem cells in development and disease
Panchision, D. M. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21812 · Cited by 250
“Likewise, in mouse embryo fibroblasts, anoxia (0.02% O2) induces p53 expression and apoptosis while hypoxia (0.2% O2) does not (Graeber et al., 1996).”
BackgroundInfluentialThe role of the 14-3-3 protein family in health, disease, and drug development
Aghazadeh, Y., & Papadopoulos, V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.012 · Cited by 250
Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine
Lipinski, K. A., Barber, L. J., Davies, M. N., Ashenden, M., Sottoriva, A., & Gerlinger, M. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.11.003 · Cited by 248
“For example, hypoxia is likely to increase in a growing tumor and can select for tumor protein p53 (TP53) mutant clones that evade apoptosis under these hostile conditions [78].”
BackgroundBlood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.
Mankoff, D. A., Dunnwald, L. K., Gralow, J. R., Ellis, G. K., Charlop, A. W., Lawton, T. J., Schubert, E. K., Tseng, J. R., & Livingston, R. B. (2002) · PubMed · Cited by 253
HIF-1: Using Two Hands to Flip the Angiogenic Switch
Semenza, G. L. (2000) · Cancer and Metastasis Reviews · doi:10.1023/a:1026544214667 · Cited by 248
“Hypoxia-mediated apoptosis provides a selection for tumor cells with p53 loss-of-function [40].”
Beasley, N. J. P., Wykoff, C. C., Watson, P. H., Leek, R., Turley, H., Gatter, K. C., Pastorek, J., Cox, G. J., Ratcliffe, P. J., & Harris, A. L. (2001) · PubMed · Cited by 252
Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia
Vāvere, A. L., & Lewis, J. S. (2007) · Dalton Transactions · doi:10.1039/b705989b · Cited by 245
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
Phillips, R. M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2920-7 · Cited by 238
“Biologically, hypoxia is implicated in promoting resistance to apoptosis [4], suppression of DNA repair pathways and promotion of genomic instability [5] increased invasion and metastasis [6], promotion of angiogenesis [7], modulation of tyrosine kinase-mediated cell signalling pathways [8], evasion Abstract The prese…”
BackgroundCytosolic drug delivery using pH- and light-sensitive liposomes
Gerasimov, O. V., Boomer, J. A., Qualls, M. M., & Thompson, D. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00035-6 · Cited by 248
Cao, D., Hou, M., Guan, Y.-S., Jiang, M., Yang, Y., & Gou, H.-F. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-432 · Cited by 244
“All these factors are under the control of HIF-1 which specially binds to the hypoxia response element (HRE) that includes cis-acting DNA elements recognized by multiple transactivators [ 11 ].”
BackgroundExpression and Role of Bcl–Xl in Human Hepatocellular Carcinomas
Takehara, T., Liu, X., Fujimoto, J., Friedman, S. L., & Takahashi, H. (2001) · Hepatology · doi:10.1053/jhep.2001.25387 · Cited by 246
Desbaillets, I., Diserens, A.-C., Tribolet, N. D., Hamou, M.-F., & Meir, E. G. V. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1201 · Cited by 243
“Furthermore, the induction was obtained irrespective of the endogenous wild-type or mutant p53 gene status of the cell lines analyzed (37), suggesting that it was not linked to hypoxia-induced p53 (38).”
BackgroundBishopric, N. H., Discher, D. J., Kaiser, S., Hernandez, O., Sato, B., Zang, J., & Webster, K. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5871 · Cited by 246
Metzger, R., Danenberg, K. D., Leichman, C. G., Salonga, D. S., Schwartz, E. L., Wadler, S., Lenz, H., Groshen, S. G., Leichman, L., & Danenberg, P. V. (1998) · PubMed · Cited by 259
Control of the cell cycle and apoptosis
Lundberg, A. S., & Weinberg, R. A. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00292-0 · Cited by 216
Targeting the ATR-CHK1 Axis in Cancer Therapy
Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 231
The oncofetal H19 RNA connection: Hypoxia, p53 and cancer
Matouk, I. J., Mezan, S., Mizrahi, A., Ohana, P., Abu-lail, R., Fellig, Y., deGroot, N., Galun, E., & Hochberg, A. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.01.010 · Cited by 239
Design of anticancer prodrugs for reductive activation
Chen, Y., & Hu, L. (2009) · Medicinal Research Reviews · doi:10.1002/med.20137 · Cited by 238
Griscelli, F., Li, H., Bennaceur-Griscelli, A., Soria, J., Opolon, P., Soria, C., Perricaudet, M., Yeh, P., & Lu, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6367 · Cited by 239
Microenvironmental and cellular consequences of altered blood flow in tumours
Raghunand, N., Gatenby, R. A., & Gillies, R. J. (2003) · The British Journal of Radiology · doi:10.1259/bjr/12913493 · Cited by 240
“Analogous to hypoxia [38], an acidic extracellular pH (pHe) provides a selective pressure towards outgrowth of apoptosis-impaired cells [70].”
BackgroundAntiangiogenic therapy and tumor progression
Blagosklonny, M. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00336-2 · Cited by 235
Lee, N. Y., Mechalakos, J. G., Nehmeh, S., Lin, Z., Squire, O. D., Cai, S., Chan, K., Zanzonico, P. B., Greco, C., Ling, C. C., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.039 · Cited by 235
Kerbel, R. S., Yu, J., Tran, J., Man, S., Viloria-Petit, A., Klement, G., Coomber, B. L., & Rak, J. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1013172910858 · Cited by 237
“Hypoxia, overall, can select for apoptosis-resistant cells [43].”
BackgroundMachein, M. R., & Plate, K. H. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006416003964 · Cited by 236
“Tumor cells that have lost functional p53 are significantly more resistant to hypoxic stress, indicating that the physiological stress of hypoxia can select for tumor cells that have lost their ability to undergo hypoxia-driven apoptosis [76].”
BackgroundSilencing of the Hypoxia-Inducible Cell Death Protein BNIP3 in Pancreatic Cancer
Okami, J., Simeone, D. M., & Logsdon, C. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0089 · Cited by 238
“However, hypoxia-related growth inhibitory mechanisms are often missing in cancer cells (7), and our data suggest that this is the case for BNIP3 expression in pancreatic cancer.”
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth
Fei, P., Wang, W., Kim, S.-H., Wang, S., Burns, T. F., Sax, J. K., Buzzai, M., Dicker, D. T., McKenna, W. G., Bernhard, E. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.012 · Cited by 231
“Wild-type p53 accumulates in deficient U2OS-E6 cells, the results argue that CBP recruitment tumor cells under hypoxic conditions (Figure 3A) and can exert is independent of p53 but may facilitate coactivation in cells an apoptotic function (Graeber et al., 1996; Graeber et al., 1994).”
BackgroundThree-dimensional multispecies nonlinear tumor growth—II: Tumor invasion and angiogenesis
Frieboes, H. B., Jin, F., Chuang, Y.-L., Wise, S. M., Lowengrub, J. S., & Cristini, V. (2010) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2010.02.036 · Cited by 232
“, 2006), may select for tumor cells that are more apoptosis resistant (Graeber et al., 1996; Yu et al., 2002), induce angiogenesis (Harris, 2002; Shweiki et al.”
BackgroundAmbs, S., Hussain, S. P., & Harris, C. C. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194524 · Cited by 233
“Not surprisingly, hypoxia, arising with tumor size, has been described to select for mutant p53 cells that are resistant to hypoxia-induced apoptosis (84).”
BackgroundFox, S. B., Gasparini, G., & Harris, A. L. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00323-5 · Cited by 230
Glucose Catabolism in Cancer Cells.
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.28.16918 · Cited by 229
“Translating” Tumor Hypoxia: Unfolded Protein Response (UPR)–Dependent and UPR-Independent Pathways
Koumenis, C., & Wouters, B. G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0150 · Cited by 228
Nordsmark, M., Alsner, J., Keller, J., Nielsen, O. S., Jensen, O. M., Horsman, M. R., & Overgaard, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1728 · Cited by 226
Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia
Suzuki, H., Tomida, A., & Tsuruo, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204742 · Cited by 223
“…in this study that apoptosis induction of MCF-7 cells requires more than 48 h of exposure to hypoxic conditions, while p53-expressing mouse embryonic ®broblasts, which were oncogenetically transformed but were not selected by hypoxia, reportedly undergo apoptosis within 24 h (Graeber et al., 1996).”
BackgroundInfluentialHypoxia/pseudohypoxia‐mediated activation of hypoxia‐inducible factor‐1α in cancer
Hayashi, Y., Yokota, A., Harada, H., & Huang, G. (2019) · Cancer Science · doi:10.1111/cas.13990 · Cited by 216
Clinical implications of p53 mutations
Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050270 · Cited by 225
Self-citationAssessment of tumor oxygenation by electron paramagnetic resonance: principles and applications
Gallez, B., Baudelet, C., & Jordan, B. F. (2004) · NMR in Biomedicine · doi:10.1002/nbm.900 · Cited by 222
Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming
Liu, J., Liu, Z.-X., Wu, Q.-N., Lu, Y.-X., Wong, C.-W., Miao, L., Wang, Y., Wang, Z., Jin, Y., He, M.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15112-3 · Cited by 226
“Because PFKFB3 contains a kinase domain and a phosphatase domain, three human FLAG-tagged PFKFB3 vectors harboring FL (1-520), N-terminal (N, 1–245) and C-terminal (C, 246–520) constructs were constructed to identify the PFKFB3 residues that associated with AGPG.”
BackgroundSaxena, K., & Jolly, M. K. (2019) · Biomolecules · doi:10.3390/biom9080339 · Cited by 216
Erythropoietin Biology in Cancer
Hardee, M. E., Arcasoy, M. O., Blackwell, K. L., Kirkpatrick, J. P., & Dewhirst, M. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1771 · Cited by 223
Signal Transduction Pathways in Apoptosis
McConkey, D. J., & Orrenius, S. (1996) · STEM CELLS · doi:10.1002/stem.140619 · Cited by 222
BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions
Chinnadurai, G., Vijayalingam, S., & Gibson, S. B. (2008) · Oncogene · doi:10.1038/onc.2009.49 · Cited by 219
“In addition to hypoxia-mediated transcriptional activation of BNIP3, the acidotic condition that occurs during ischemia was also reported to contribute to BNIP3-dependent death of myocytes (Graham et al., 2004).”
An evolutionary hybrid cellular automaton model of solid tumour growth
Gerlee, P., & Anderson, A. R. A. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.01.027 · Cited by 220
“Some of these predictions are in agreement with recent experimental results, in particular Graeber et al. (1996), Kim et al. (1997) show that cancer cells from hypoxic tumours have a smaller apoptotic potential.”
BackgroundResultAutophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy
Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A., & O'Dwyer, P. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1542 · Cited by 221
“Furthermore, cells in hypoxic environments have been shown to accumulate mutations and more aggressive growth characteristics (14, 15).”
BackgroundEbbesen, P., Pettersen, E. O., Gorr, T. A., Jobst, G., Williams, K., Kieninger, J., Wenger, R. H., Pastorekova, S., Dubois, L., Lambin, P., et al. (2009) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360902784425 · Cited by 218
Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth
Rak, J., Yu, J. L., Klement, G., & Kerbel, R. S. (2000) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2000.00012.x · Cited by 222
Airley, R. E., Loncaster, J., Raleigh, J. A., Harris, A. L., Davidson, S. E., Hunter, R. D., West, C. M. L., & Stratford, I. J. (2003) · International Journal of Cancer · doi:10.1002/ijc.10904 · Cited by 221
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas
Becker, A., Stadler, P., Lavey, R. S., Hänsgen, G., Kuhnt, T., Lautenschläger, C., Feldmann, H. J., Molls, M., & Dunst, J. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00384-3 · Cited by 218
Lluis, J. M., Buricchi, F., Chiarugi, P., Morales, A., & Fernandez-Checa, J. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0515 · Cited by 221
“Moreover, although cells transfected with the control siRNA were resistant to 5% O2, as expected based on previous findings ( 38 ), HepG2 cells transfected with p65 siRNA exhibited a significant susceptibility to hypoxia-induced cell death (Fig. 3D).”
BackgroundResultSpatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 203
“Another cell-extrinsic and environmental factor influencing cancer evolution is hypoxia, the often localized depletion of oxygen in tumours; it is well established as a marker of poor outcomes(174) and has been shown to select for certain mutations such as TP53 (ref.(175)).”
BackgroundCairns, R. A., & Hill, R. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3196 · Cited by 216
“There are at least the following two possibilities: (a) that the treatment is accelerating mutation and exerting a selective pressure that encourages the outgrowth of more aggressive cellular variants ( 54 , 55), or ( b) that the stress associated with the treatment is inducing epigenetic changes such as alterations i…”
BackgroundErkan, M., Kleeff, J., Esposito, I., Giese, T., Ketterer, K., Büchler, M. W., Giese, N. A., & Friess, H. (2005) · Oncogene · doi:10.1038/sj.onc.1208642 · Cited by 217
“…rests on the facts that: (a) hypoxia increases the mutational rate in the cells and (b) cells which gained a survival advantage by resisting apoptosis under hypoxic conditions also became more resistant to cancer therapy (Graeber et al., 1996; Reynolds et al., 1996; Schmaltz et al., 1998).”
BackgroundRegulation of Proliferation-Survival Decisions during Tumor Cell Hypoxia
Schmaltz, C., Hardenbergh, P. H., Wells, A., & Fisher, D. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.5.2845 · Cited by 217
“Our results are consistent with the hypothesis that this form of apoptosis is modulated by the presence or absence of p53 (19).”
BackgroundMethodResultInfluentialA New Role for Hypoxia in Tumor Progression
Coquelle, A., Toledo, F., Stern, S., Bieth, A., & Debatisse, M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80137-9 · Cited by 215
Targeting the hypoxia-inducible factor (HIF) pathway in cancer
Poon, E., Harris, A. L., & Ashcroft, M. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001173 · Cited by 213
In vitro cancer cell–ECM interactions inform in vivo cancer treatment
Holle, A. W., Young, J. L., & Spatz, J. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.007 · Cited by 213
Mitochondrial Akt Regulation of Hypoxic Tumor Reprogramming
Chae, Y. C., Vaira, V., Caino, M. C., Tang, H.-Y., Seo, J. H., Kossenkov, A. V., Ottobrini, L., Martelli, C., Lucignani, G., Bertolini, I., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.004 · Cited by 209
“Hypoxia is a nearly universal feature of tumor growth (Hockel and Vaupel, 2001), conferring worse disease outcome via protection from apoptosis (Graeber et al., 1996), resistance to therapy (Tredan et al.”
BackgroundOpening doors with ultrasound and microbubbles: Beating biological barriers to promote drug delivery
Deprez, J., Lajoinie, G., Engelen, Y., De Smedt, S. C., & Lentacker, I. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.015 · Cited by 207
The role of p53 in hypoxia-induced apoptosis
Hammond, E. M., & Giaccia, A. J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.154 · Cited by 205
Self-citationp53; from inductive signal to cellular effect
Hansen, R., & Oren, M. (1997) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(97)80108-6 · Cited by 213
Knocke, T.-H., Weitmann, H.-D., Feldmann, H.-J., Selzer, E., & Pötter, R. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00139-5 · Cited by 210
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death
Graham, N. A., Tahmasian, M., Kohli, B., Komisopoulou, E., Zhu, M., Vivanco, I., Teitell, M. A., Wu, H., Ribas, A., Lo, R. S., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.20 · Cited by 211
“In a manner similar to the hypoxic selection of cells with increased resistance to apoptosis (Graeber et al, 1996), intermittent glucose deprivation could select against cells dependent on glucose for survival.”
Self-citationInvolvement of Hypoxia-Inducible Factor 1 in Human Cancer.
SEMENZA, G. L. (2002) · Internal Medicine · doi:10.2169/internalmedicine.41.79 · Cited by 208
Levy, R., Smith, S. D., Chandler, K., Sadovsky, Y., & Nelson, D. M. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.278.5.c982 · Cited by 211
Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress
Zundel, W., & Giaccia, A. (1998) · Genes & Development · doi:10.1101/gad.12.13.1941 · Cited by 209
“PI(3)K down-regulation by stress is dependent on acid–sphingomyelinase Generation of ceramide in response to stress is catalyzed by several distinct sphingomyelinases that are characterized by their activity at distinct pH ranges and their requirement for divalent cations (Hannun 1996).”
BackgroundSelf-citationBroxterman, H. J., Gotink, K. J., & Verheul, H. M. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.07.001 · Cited by 209
Büchler, P., Reber, H. A., Büchler, M., Shrinkante, S., Büchler, M. W., Friess, H., Semenza, G. L., & Hines, O. J. (2003) · Pancreas · doi:10.1097/00006676-200301000-00010 · Cited by 206
“hypoxia on gene expression and the growth of cancer cells were studied, and the results suggest a more active role of hypoxia in tumor biology (9,11,26).”
BackgroundEnergy Metabolism during Apoptosis
Garland, J. M., & Halestrap, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.8.4680 · Cited by 207
Koch, C. J. (2002) · Methods in Enzymology · doi:10.1016/s0076-6879(02)52003-6 · Cited by 207
Self-citationOxygen in Health and Disease: Regulation of Oxygen Homeostasis-Clinical Implications
Maltepe, E., & Saugstad, O. D. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31818fc83f · Cited by 200
“21%), mitochondrial electron transport of cultured cells is inhibited and apoptotic death is initiated (1,2).”
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.